In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers?

Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 54
• Zuranolone for the Treatment of Postpartum Depression